Midazolam Pharmacology

Quick Answer

Midazolam is a water-soluble imidazobenzodiazepine that acts as a positive allosteric modulator of GABA-A receptors at the alpha-gamma subunit interface, enhancing chloride conductance to produce anxiolysis, amnesia, sedation, and anticonvulsant effects. Its unique physicochemical property is pH-dependent lipophilicity: water-soluble at pH less than 4 (allowing stable aqueous formulation) but lipid-soluble at physiological pH 7.4 (enabling rapid CNS penetration). Following IV administration, onset occurs in 2-3 minutes with peak effect at 3-5 minutes. Midazolam undergoes extensive hepatic metabolism via CYP3A4 to the active metabolite 1-hydroxymidazolam, which is subsequently glucuronidated and renally excreted. The elimination half-life is 1.5-2.5 hours in healthy adults, though this is prolonged in elderly patients, hepatic impairment, and critical illness. Clinical applications include premedication (0.5-1 mg/kg PO in children, 1-2 mg IV in adults), procedural sedation (0.5-2 mg IV titrated), co-induction with propofol (0.03-0.05 mg/kg), ICU sedation (0.03-0.2 mg/kg/hr), and treatment of status epilepticus (0.15-0.2 mg/kg IV/IM/IN). The specific benzodiazepine antagonist flumazenil reverses midazolam's effects but carries re-sedation risk due to its shorter half-life. Major drug interactions occur with CYP3A4 inhibitors (erythromycin, ketoconazole, ritonavir) which significantly prolong midazolam effect. [1-8]

Chemical Structure and Classification

Imidazobenzodiazepine Structure

Midazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine) is a short-acting benzodiazepine belonging to the imidazobenzodiazepine subclass. First synthesised by Fryer and Walser at Hoffmann-La Roche in 1975 and introduced clinically in 1982, midazolam represented a significant advance over earlier benzodiazepines due to its water solubility and rapid onset. The molecular structure consists of a benzodiazepine core (seven-membered ring fused to a benzene ring) with a fused imidazole ring at positions 1 and 2. This imidazole ring confers the unique pH-dependent physicochemical properties that distinguish midazolam from classical benzodiazepines such as diazepam. The fluorine atom at the 2-fluorophenyl substituent and chlorine at position 8 enhance receptor binding affinity. The molecular weight is 325.8 Da, and the compound exists as a weak base with a pKa of 6.15. [9-12]

Molecular Properties:

pH-Dependent Physicochemical Properties

The defining characteristic of midazolam is its pH-dependent conformational change and resultant lipophilicity. At acidic pH (less than 4), the imidazole ring opens, creating a charged, water-soluble structure that allows formulation as a stable aqueous solution without organic solvents. At physiological pH (7.35-7.45), the imidazole ring closes, converting midazolam to a highly lipophilic, uncharged molecule that rapidly crosses the blood-brain barrier. [13-15]

pH-Dependent Properties:

This property provides two major clinical advantages:

1. Stable aqueous formulation: Unlike diazepam (requiring propylene glycol solvent), midazolam can be formulated in water-based solutions, reducing injection site pain and venous irritation
2. Rapid onset: At physiological pH, the lipophilic form rapidly crosses the blood-brain barrier, producing onset of action within 2-3 minutes IV (compared to 3-5 minutes for diazepam)

Comparison with Other Benzodiazepines

Mechanism of Action

GABA-A Receptor Structure

The GABA-A receptor is a pentameric ligand-gated chloride ion channel that mediates fast inhibitory neurotransmission in the central nervous system. The receptor complex typically comprises two alpha subunits, two beta subunits, and one gamma subunit (most commonly the alpha-1, beta-2, gamma-2 configuration, representing approximately 60% of brain GABA-A receptors). Multiple alpha subunit isoforms (alpha-1 through alpha-6) and gamma subunit isoforms (gamma-1 through gamma-3) exist, with different combinations producing receptors with distinct pharmacological properties and regional distributions. [16-18]

GABA-A Receptor Binding Sites:

Positive Allosteric Modulation

Midazolam acts as a positive allosteric modulator (PAM) at the benzodiazepine binding site located at the interface between alpha and gamma-2 subunits. This mechanism differs fundamentally from direct receptor agonism:

Molecular Mechanism:

1. Midazolam binds with high affinity (Ki = 2-5 nM) to the alpha-gamma-2 subunit interface
2. Binding induces a conformational change in the receptor complex
3. This conformational change increases the affinity of the GABA binding site for GABA
4. When GABA binds (required for effect), chloride channel opening frequency increases
5. Increased chloride influx causes membrane hyperpolarisation
6. Neuronal excitability is reduced

Critical Distinction from Barbiturates and Propofol:

• Benzodiazepines increase the frequency of chloride channel opening
• Barbiturates increase the duration of chloride channel opening
• At high concentrations, barbiturates and propofol can directly activate GABA-A receptors without GABA
• Benzodiazepines have no intrinsic activity without GABA (GABA-dependent effect)

This GABA-dependence explains the ceiling effect and relative safety of benzodiazepines: as GABA becomes depleted at high doses, further receptor modulation is limited, reducing respiratory depression risk compared to barbiturates. [19-22]

Alpha Subunit Selectivity and Clinical Effects

The specific clinical effects of midazolam correlate with GABA-A receptor subtypes defined by their alpha subunit composition. Midazolam binds to receptors containing alpha-1, alpha-2, alpha-3, and alpha-5 subunits (all with gamma-2), but not alpha-4 or alpha-6 subunits (which lack the histidine residue required for benzodiazepine binding). [23-25]

Subunit-Specific Effects:

The profound anterograde amnesia produced by midazolam is mediated primarily through alpha-1 and alpha-5 containing receptors in the hippocampus. The alpha-5 subtype, although representing only 5% of brain GABA-A receptors, is concentrated in the hippocampus and plays a disproportionate role in memory processes.

Dose-Response Relationships

Midazolam demonstrates a characteristic sigmoid dose-response relationship with distinct clinical endpoints occurring at different plasma concentrations:

The steep dose-response curve means small dose increments can produce large changes in effect, particularly when transitioning from sedation to hypnosis. This necessitates careful titration, especially in elderly and critically ill patients.

Pharmacokinetics

Absorption and Routes of Administration

Midazolam demonstrates route-dependent absorption characteristics that influence clinical use:

Intravenous Administration:

• 100% bioavailability by definition
• Onset: 2-3 minutes (one arm-brain circulation time)
• Peak effect: 3-5 minutes
• Preferred route for procedural sedation and acute situations

Intramuscular Administration:

• Bioavailability: 90-100%
• Onset: 5-15 minutes
• Peak effect: 15-30 minutes
• Reliable absorption from deltoid or vastus lateralis
• Useful when IV access unavailable

Intranasal Administration:

• Bioavailability: 50-75%
• Onset: 5-10 minutes
• Peak effect: 10-20 minutes
• Dose: 0.2-0.3 mg/kg (using IV formulation or concentrated nasal spray)
• Effective for paediatric premedication and acute seizure management
• Limited by nasal irritation from acidic formulation

Oral Administration:

• Bioavailability: 30-50% (extensive first-pass metabolism)
• Onset: 15-30 minutes
• Peak effect: 30-60 minutes
• Dose: 0.25-0.5 mg/kg (children), 7.5-15 mg (adults)
• Commonly used for paediatric premedication

Rectal Administration:

• Bioavailability: 40-50%
• Onset: 10-20 minutes
• Used in paediatric seizure management when IV/IN unavailable

Buccal/Sublingual Administration:

• Bioavailability: 75%
• Onset: 5-15 minutes
• Avoids first-pass metabolism
• Useful in paediatric seizures (Buccolam preparation)

Distribution

Following intravenous administration, midazolam distributes rapidly according to a two- or three-compartment pharmacokinetic model:

Factors Affecting Distribution:

1. Protein binding changes: Hypoalbuminaemia (liver disease, nephrotic syndrome, critical illness) increases free fraction, potentially enhancing effect
2. Cardiac output: Reduced cardiac output (heart failure, shock) prolongs arm-brain circulation time and slows onset but may increase brain concentration
3. Age: Elderly patients have reduced Vd due to reduced muscle mass and increased body fat, increasing plasma concentrations
4. Obesity: Lipophilic drug accumulates in adipose tissue; Vd increases with obesity, potentially prolonging elimination

Metabolism

Midazolam undergoes extensive hepatic biotransformation primarily via the cytochrome P450 system, with CYP3A4 being the predominant enzyme. This metabolic pathway has major clinical implications for drug interactions. [26-28]

Primary Metabolic Pathway:

Midazolam
    |
    v (CYP3A4, CYP3A5)
1-Hydroxymidazolam (active, 60-80% potency of parent)
    |
    v (UGT2B4, UGT2B7 - glucuronidation)
1-Hydroxymidazolam glucuronide (inactive, water-soluble)
    |
    v (renal excretion)
Urine (60-80% of dose)

Secondary Metabolic Pathway:

Midazolam
    |
    v (CYP3A4)
4-Hydroxymidazolam (inactive or minimal activity)
    |
    v (glucuronidation)
4-Hydroxymidazolam glucuronide
    |
    v (renal excretion)
Urine

Key Metabolic Features:

1-Hydroxymidazolam: The Active Metabolite

1-Hydroxymidazolam is pharmacologically active with approximately 60-80% of the potency of the parent compound. Under normal circumstances, its contribution to overall effect is limited because:

• It undergoes rapid glucuronidation
• Its plasma half-life is shorter than midazolam

However, in two clinical scenarios, 1-hydroxymidazolam becomes clinically significant:

1. Renal failure: The glucuronide metabolite accumulates and may be deconjugated to release active 1-hydroxymidazolam, prolonging sedation
2. Critical illness: Reduced glucuronidation capacity may increase 1-hydroxymidazolam levels

Elimination

The relatively short elimination half-life of midazolam (compared to diazepam's 20-100 hours) makes it more suitable for procedural sedation and ICU use, though in critically ill patients, context-sensitive half-time increases significantly with prolonged infusions.

Pharmacokinetics in Special Populations

Elderly Patients:

• Reduced hepatic blood flow and CYP3A4 activity decrease clearance by 30-50%
• Reduced Vd increases peak plasma concentration
• Increased CNS sensitivity (pharmacodynamic change)
• Dose reduction of 30-50% recommended
• Onset may be delayed due to reduced cardiac output
• Duration significantly prolonged

Paediatric Patients:

• Neonates (less than 1 month): Immature CYP3A4/3A7 systems, reduced clearance, prolonged half-life (6-12 hours)
• Infants (1-6 months): Maturing metabolism, half-life 3-6 hours
• Children (greater than 1 year): Higher weight-normalised clearance than adults, may need higher mg/kg doses
• Adolescents: Approach adult pharmacokinetics

Critically Ill Patients:

• Multiple factors prolong effect: reduced hepatic blood flow, reduced CYP3A4 activity, hypoalbuminaemia, accumulation of active metabolite
• Context-sensitive half-time increases dramatically with prolonged infusions (greater than 24-48 hours)
• Daily sedation interruption reveals accumulated drug effect
• Half-life may exceed 24-48 hours after prolonged infusions

Obesity:

• Loading dose based on total body weight (TBW) or ideal body weight plus 40% excess
• Maintenance infusion based on ideal body weight (IBW)
• Increased Vd prolongs elimination
• Accumulation in adipose tissue with prolonged infusions

Hepatic Impairment:

• Reduced first-pass metabolism increases oral bioavailability to 60-80%
• Reduced clearance (50-75% reduction in cirrhosis)
• Prolonged half-life (4-12 hours)
• Reduce dose by 50% and titrate carefully
• Increased risk of hepatic encephalopathy precipitation

Renal Impairment:

• Parent drug pharmacokinetics minimally affected (less than 1% renal excretion)
• 1-hydroxymidazolam glucuronide accumulates in severe renal failure
• May cause prolonged sedation through deconjugation to active metabolite
• Monitor closely; reduce dose if prolonged sedation observed

Pharmacodynamics: System Effects

Central Nervous System Effects

Sedation and Hypnosis: Midazolam produces dose-dependent CNS depression ranging from anxiolysis to deep sedation. The sedation is characterised by:

• Drowsiness and decreased awareness
• Reduced psychomotor performance
• Impaired cognitive function
• Obtunded response to verbal commands at higher doses
• Loss of consciousness at hypnotic doses

Amnesia: Anterograde amnesia is one of midazolam's most clinically useful properties, occurring at plasma concentrations that do not necessarily produce sedation. This selective amnesia:

• Is anterograde (affects new memory formation, not recall of existing memories)
• Begins within 2-5 minutes of IV administration
• Lasts 20-40 minutes after single bolus (longer with repeat doses or infusion)
• Is mediated primarily through alpha-5 GABA-A receptors in the hippocampus
• Is more profound than with equivalent sedative doses of propofol

Anxiolysis: Anxiolytic effects occur at subhypnotic doses, mediated primarily through alpha-2 and alpha-3 containing GABA-A receptors in the limbic system. This makes midazolam valuable for premedication.

Anticonvulsant Activity: Midazolam has potent anticonvulsant properties through enhancement of GABAergic inhibition:

• First-line agent for status epilepticus (with lorazepam)
• Effective via multiple routes (IV, IM, IN, buccal)
• Intramuscular midazolam equivalent or superior to IV lorazepam in prehospital seizure termination (RAMPART trial)
• Tolerance develops with prolonged use

Cerebral Effects:

• Reduces cerebral metabolic rate for oxygen (CMRO2) by 15-25%
• Reduces cerebral blood flow proportionally
• Minimal effect on intracranial pressure in most patients
• Does not produce burst suppression or isoelectric EEG

Muscle Relaxation: Central muscle relaxant effect occurs through enhancement of spinal cord GABA-A receptors (alpha-2 and alpha-3 subtypes), but the effect is modest compared to dedicated muscle relaxants.

Cardiovascular Effects

Midazolam produces mild cardiovascular depression that is generally well-tolerated in most patients but can be significant in hypovolaemic or critically ill patients:

Comparison with Other Agents:

The cardiovascular depression is additive with opioids and potentiated by hypovolaemia, pre-existing cardiac disease, and advanced age. Pre-hydration and careful titration are recommended in at-risk patients.

Respiratory Effects

Respiratory depression is the most significant adverse effect of midazolam and the primary safety concern:

Ventilatory Effects:

• Dose-dependent reduction in tidal volume and respiratory rate
• Decreased ventilatory response to hypercapnia (CO2 sensitivity reduced)
• Decreased ventilatory response to hypoxia
• Apnoea possible at high doses or rapid administration
• Upper airway muscle tone reduced (potential for obstruction)

Risk Factors for Respiratory Depression:

1. Concurrent opioid administration (synergistic depression)
2. Elderly patients (increased sensitivity)
3. Obstructive sleep apnoea
4. Chronic respiratory disease (COPD, severe asthma)
5. Obesity (mechanical disadvantage)
6. Rapid IV administration
7. Pre-existing sedation

Comparison of Respiratory Effects:

Continuous monitoring with pulse oximetry and capnography is recommended during midazolam sedation, particularly when combined with opioids.

Clinical Applications

Premedication

Midazolam is the most commonly used premedicant in modern anaesthetic practice:

Oral Premedication (Paediatric):

• Dose: 0.25-0.5 mg/kg (maximum 20 mg)
• Timing: 20-30 minutes before induction
• Advantages: Anxiolysis, amnesia, parental separation facilitated
• Formulation: Oral solution (2 mg/mL) or IV formulation mixed with sweet syrup

Intravenous Premedication (Adult):

• Dose: 1-2 mg IV, titrated
• Timing: 2-5 minutes before induction
• Advantages: Reduces propofol induction dose by 25-50%, provides anxiolysis

Intranasal Premedication (Paediatric):

• Dose: 0.2-0.3 mg/kg
• Advantages: Non-invasive, rapid absorption
• Disadvantages: Nasal irritation, unpredictable depth

Procedural Sedation

Midazolam is widely used for procedural sedation in endoscopy, radiology, emergency department, and minor surgical procedures:

Dosing Protocol:

1. Initial dose: 0.5-1 mg IV (elderly: 0.25-0.5 mg)
2. Wait 2-3 minutes for peak effect
3. Titrate with 0.5-1 mg increments every 2-3 minutes
4. Target: Responsive to verbal commands, eyes closing
5. Total dose typically 2.5-7.5 mg for most procedures

Combination with Opioids: Fentanyl (25-50 mcg) or alfentanil (250-500 mcg) commonly co-administered for analgesia. This combination produces synergistic sedation and respiratory depression - dose reductions of both drugs required.

Advantages for Procedural Sedation:

• Profound amnesia (patient comfort)
• Anxiolysis
• Reversible with flumazenil
• Relatively short duration

Disadvantages:

• Unpredictable depth in some patients
• Respiratory depression (especially with opioids)
• No analgesia (opioid required for painful procedures)
• Paradoxical reactions (rare)

Co-Induction with Propofol

Midazolam is used as a co-induction agent to reduce propofol requirements:

Mechanism:

• Synergistic interaction at GABA-A receptor (different binding sites)
• Reduces propofol ED50 by 50-60%
• Enhances amnesia

Dosing:

• Midazolam 0.03-0.05 mg/kg IV, 2-3 minutes before propofol
• Followed by reduced propofol dose (1-1.5 mg/kg instead of 2-2.5 mg/kg)

Advantages:

• Reduced propofol dose (cost saving)
• Reduced propofol-induced hypotension
• Enhanced amnesia

Disadvantages:

• Prolonged emergence compared to propofol alone
• Additional drug preparation

ICU Sedation

Midazolam remains used for ICU sedation despite trends toward propofol and dexmedetomidine:

Infusion Protocol:

• Loading dose: 0.03-0.05 mg/kg IV
• Maintenance: 0.03-0.2 mg/kg/hr (typically 1-7 mg/hr)
• Titrate to RASS -1 to -3 or equivalent sedation scale

Advantages:

• Anxiolysis and amnesia
• Anticonvulsant properties
• Lower cost than propofol/dexmedetomidine
• No propofol infusion syndrome risk

Disadvantages:

• Accumulation with prolonged infusion (greater than 48-72 hours)
• Context-sensitive half-time increases dramatically
• Prolonged awakening after discontinuation
• Delirium association (SEDCOM, MIDEX/PRODEX trials)
• Tolerance and withdrawal with prolonged use

Modern ICU Practice: Current guidelines (PADIS 2018) favour light sedation targets and non-benzodiazepine agents (propofol, dexmedetomidine) for most patients. Midazolam remains appropriate for:

• Patients requiring deep sedation (severe ARDS, therapeutic hypothermia)
• Seizure prophylaxis/treatment
• Alcohol withdrawal
• Cost-constrained settings

Status Epilepticus

Midazolam is a first-line agent for status epilepticus management:

RAMPART Trial Evidence:

• IM midazolam (10 mg) equivalent or superior to IV lorazepam (4 mg) for prehospital seizure termination
• Faster administration (no IV access required) led to earlier seizure termination

Dosing for Status Epilepticus:

Refractory Status Epilepticus: Midazolam infusion (0.1-0.4 mg/kg/hr, titrated to EEG burst suppression) is used for refractory status epilepticus when first-line agents fail.

Flumazenil: Reversal of Midazolam

Mechanism of Action

Flumazenil is a competitive antagonist at the benzodiazepine binding site on GABA-A receptors. It has high affinity for the alpha-gamma-2 interface but no intrinsic activity (neutral antagonist). Flumazenil displaces midazolam and reverses its effects without affecting other GABAergic drugs (propofol, barbiturates). [1,5]

Pharmacokinetics

Clinical Use

Dosing Protocol:

1. Initial: 0.2 mg IV over 15-30 seconds
2. Wait 45-60 seconds
3. Repeat: 0.2 mg increments at 60-second intervals
4. Maximum: 1 mg (procedural sedation), 3-5 mg (overdose)

Indications:

• Reversal of procedural sedation (selected cases)
• Diagnostic trial in suspected benzodiazepine overdose
• Reversal of paradoxical benzodiazepine reactions
• Iatrogenic oversedation

Re-Sedation Risk

Critical Concept: Flumazenil has a shorter half-life (40-80 minutes) than midazolam (1.5-2.5 hours). After flumazenil wears off, remaining midazolam can re-occupy receptors, causing:

• Recurrence of sedation
• Recurrence of respiratory depression
• Recurrence of amnesia

Prevention and Management:

• Monitor for minimum 2 hours post-flumazenil
• Consider repeat dosing or infusion (0.1-0.4 mg/hr) for long-acting benzodiazepines
• Avoid routine flumazenil use (reserve for specific indications)

Contraindications to Flumazenil

Drug Interactions

CYP3A4-Mediated Interactions

Midazolam's metabolism via CYP3A4 creates clinically significant drug interactions:

CYP3A4 Inhibitors (Increase Midazolam Effect):

Clinical Management with CYP3A4 Inhibitors:

• Reduce midazolam dose by 50-75%
• Titrate carefully
• Consider alternative sedative (lorazepam - glucuronidation only, no CYP3A4 metabolism)
• Avoid oral midazolam with potent inhibitors (unpredictable absorption)

CYP3A4 Inducers (Decrease Midazolam Effect):

Clinical Management with CYP3A4 Inducers:

• Significantly increased doses may be required
• Unpredictable response
• Consider alternative agents
• IV administration partially bypasses first-pass induction effect

Pharmacodynamic Interactions

Synergistic CNS Depression:

Special Populations

Elderly Patients

Pharmacokinetic Changes:

• Reduced clearance (30-50%)
• Reduced Vd
• Higher peak concentrations
• Prolonged half-life (2.5-4.5 hours)

Pharmacodynamic Changes:

• Increased CNS sensitivity
• Enhanced sedative effect at lower concentrations

Dosing Recommendations:

• Reduce initial dose by 50%
• Titrate slowly (longer intervals between doses)
• Expect prolonged duration
• Monitor closely for respiratory depression
• Consider alternatives (reduced doses of propofol with faster offset)

Hepatic Impairment

Child-Pugh A (Mild):

• Modest prolongation of half-life
• Reduce dose by 25%
• Standard monitoring

Child-Pugh B-C (Moderate-Severe):

• Markedly reduced clearance (50-75%)
• Increased oral bioavailability (60-80%)
• Risk of hepatic encephalopathy
• Reduce dose by 50-75%
• Consider lorazepam (glucuronidation only)
• Extended monitoring

Renal Impairment

Mild-Moderate (CrCl 30-60 mL/min):

• Parent drug pharmacokinetics largely unchanged
• Standard dosing for single doses
• Monitor for metabolite accumulation with infusions

Severe/ESRD (CrCl less than 30 mL/min):

• 1-hydroxymidazolam glucuronide accumulates
• May deconjugate to active 1-hydroxymidazolam
• Prolonged sedation reported after infusions
• Reduce infusion doses; monitor closely
• Consider daily sedation interruption

Obesity

Loading Dose:

• Use adjusted body weight: IBW + 0.4 × (TBW - IBW)
• Or use total body weight with careful titration

Maintenance Infusion:

• Base on ideal body weight
• Titrate to effect
• Accumulation in adipose tissue prolongs elimination

Considerations:

• Often have obstructive sleep apnoea (increased sensitivity to respiratory depression)
• May have fatty liver disease (reduced metabolism)
• Non-linear pharmacokinetics in morbid obesity

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Populations

Specific pharmacogenomic data for midazolam in Aboriginal and Torres Strait Islander populations remain limited. However, several clinical factors warrant careful consideration when administering midazolam to Indigenous patients.

Higher prevalence of chronic liver disease, including alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease, may significantly impair midazolam metabolism via reduced CYP3A4 activity. In patients with suspected hepatic impairment, dose reductions of 25-50% are prudent, with careful titration and extended monitoring for delayed recovery. Chronic kidney disease, affecting Aboriginal and Torres Strait Islander peoples at 3-4 times the rate of non-Indigenous Australians, can lead to accumulation of the active metabolite 1-hydroxymidazolam glucuronide, potentially prolonging sedation after infusions; close monitoring and consideration of dose reduction are appropriate.

Cultural safety principles are essential when administering sedative medications. The altered state of consciousness during sedation and amnesia may have particular significance requiring sensitive explanation using culturally appropriate language. Involvement of Aboriginal Health Workers or Hospital Liaison Officers can facilitate communication and build trust. Family presence during induction and recovery should be accommodated consistent with kinship structures and community expectations. Clear explanation of expected amnesia and recovery timeline helps reduce anxiety for patients and family members. In remote settings, limited monitoring capabilities favour conservative dosing and may make midazolam preferable to propofol due to its reversibility with flumazenil.

Maori Health Considerations

For Maori patients in Aotearoa New Zealand, engagement with whanau during discussions about sedation and anaesthesia recognises the collective nature of health decision-making. Similar considerations regarding hepatic and renal disease prevalence apply, with appropriate dose modifications. Cultural protocols around altered states of consciousness should be respected, and karakia (prayer) or other practices may be incorporated where requested by the patient and family.

ANZCA Primary Exam Focus

High-Yield MCQ Topics

1. pH-dependent physicochemistry: Water-soluble at pH less than 4 (open ring), lipid-soluble at pH 7.4 (closed ring)
2. Mechanism: Positive allosteric modulator at alpha-gamma-2 interface of GABA-A receptor; increases frequency of chloride channel opening; GABA-dependent (no intrinsic activity without GABA)
3. Metabolism: CYP3A4 to active 1-hydroxymidazolam; glucuronidation; renal excretion of metabolites
4. Drug interactions: CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir) dramatically increase effect
5. Flumazenil: Competitive antagonist; shorter half-life causes re-sedation risk; contraindicated in chronic BZD dependence
6. Half-life comparison: Midazolam 1.5-2.5 hours vs diazepam 20-100 hours vs lorazepam 10-20 hours

Primary Viva Question Themes

Structure-Activity:

• Describe the chemical structure of midazolam and explain how pH affects its physicochemical properties
• Why is midazolam water-soluble at low pH but lipophilic at physiological pH?

Mechanism:

• Compare and contrast the mechanism of action of midazolam and propofol at the GABA-A receptor
• Explain why benzodiazepines have a ceiling effect for respiratory depression compared to barbiturates

Pharmacokinetics:

• Describe the metabolism of midazolam and the clinical significance of its metabolites
• How would hepatic or renal impairment affect midazolam pharmacokinetics?

Drug Interactions:

• A patient is receiving erythromycin for pneumonia. How would this affect your midazolam dosing?
• List CYP3A4 inhibitors and explain the mechanism of interaction with midazolam

Clinical Scenarios:

• Describe your approach to procedural sedation with midazolam
• When would you consider using flumazenil, and what are the risks?

Calculation Questions

Example 1: ICU Sedation A 70 kg patient requires midazolam sedation at 0.1 mg/kg/hr. What infusion rate in mg/hr and mL/hr (using 1 mg/mL solution) should be set?

Answer:

• Dose = 0.1 mg/kg/hr × 70 kg = 7 mg/hr
• Using 1 mg/mL: Rate = 7 mL/hr

Example 2: Paediatric Premedication Calculate the oral midazolam dose for a 20 kg child using 0.5 mg/kg.

Answer:

• Dose = 0.5 mg/kg × 20 kg = 10 mg
• Using 2 mg/mL oral solution: Volume = 10 mg ÷ 2 mg/mL = 5 mL

Assessment Content

SAQ Practice Question (20 marks)

Question:

A 78-year-old woman (55 kg) requires sedation for upper gastrointestinal endoscopy. She has a history of chronic kidney disease (eGFR 25 mL/min/1.73m²) and is taking diltiazem for atrial fibrillation. Her baseline blood pressure is 135/75 mmHg.

(a) Describe the mechanism of action of midazolam at the molecular level, distinguishing it from propofol. (5 marks)

(b) Explain how this patient's renal impairment and diltiazem therapy will affect midazolam pharmacokinetics, and outline your dosing strategy. (5 marks)

(c) During the procedure, the patient becomes unresponsive with SpO2 falling to 85%. Describe your immediate management and the role of flumazenil. (5 marks)

(d) The patient awakens appropriately after flumazenil but becomes sedated again 45 minutes later. Explain the pharmacokinetic basis for this phenomenon and your management. (5 marks)

---

Model Answer:

(a) Mechanism of Action (5 marks)

Midazolam Mechanism (2.5 marks):

• Midazolam acts as a positive allosteric modulator (PAM) at GABA-A receptors
• Binds to the benzodiazepine site at the alpha-gamma-2 subunit interface (distinct from GABA binding site)
• Binding increases receptor affinity for GABA (does not directly activate receptor)
• When GABA binds, chloride channel opening frequency is increased (not duration)
• Results in enhanced chloride influx, membrane hyperpolarisation, and reduced neuronal excitability
• GABA-dependent effect: no intrinsic activity without GABA (explains ceiling effect and relative safety)

Propofol Mechanism - Distinction (2.5 marks):

• Propofol also acts as a positive allosteric modulator at GABA-A receptors
• However, propofol binds to beta-subunit (not alpha-gamma interface)
• Propofol increases duration of chloride channel opening (not frequency)
• At higher concentrations, propofol can directly activate GABA-A receptors without GABA
• This lack of GABA-dependence explains propofol's greater potential for profound respiratory depression
• Propofol also acts at other targets (NMDA receptors, glycine receptors)

(b) Pharmacokinetics and Dosing Strategy (5 marks)

Renal Impairment Effect (2 marks):

• Parent midazolam pharmacokinetics minimally affected by renal impairment (less than 1% renal excretion)
• However, 1-hydroxymidazolam glucuronide (major metabolite) accumulates in severe renal failure
• This inactive glucuronide can undergo deconjugation, releasing active 1-hydroxymidazolam
• Risk of prolonged sedation, particularly after repeated doses or infusions
• Clinical significance uncertain for single procedural doses but warrants caution

Diltiazem Interaction (1.5 marks):

• Diltiazem is a moderate CYP3A4 inhibitor
• Midazolam is primarily metabolised by CYP3A4 to 1-hydroxymidazolam
• Co-administration increases midazolam AUC by 2-3 fold
• Prolongs half-life and increases peak concentrations
• Requires dose reduction

Dosing Strategy (1.5 marks):

• Reduce initial dose by 50-75%: 0.25-0.5 mg IV initially (instead of 1-2 mg)
• Wait at least 3 minutes between doses (increased time to peak effect in elderly)
• Titrate in 0.25-0.5 mg increments
• Expected total dose: 1-2 mg (significantly less than standard)
• Continuous SpO2 and capnography monitoring
• Consider alternative agent (propofol with faster offset) if available

(c) Immediate Management and Flumazenil (5 marks)

Immediate Management (3 marks):

1. Stop procedure and stimulate patient verbally/physically
2. Ensure patent airway: head tilt-chin lift, jaw thrust, consider oropharyngeal airway
3. Administer high-flow oxygen (100%)
4. Assist ventilation with bag-valve-mask if apnoeic or severe hypoxia persists
5. Consider calling for anaesthetic assistance
6. Prepare for possible intubation if not responding

Flumazenil Role (2 marks):

• Indicated for reversal of benzodiazepine-induced respiratory depression
• Initial dose: 0.2 mg IV over 15-30 seconds
• Wait 45-60 seconds, repeat 0.2 mg if inadequate response
• Expected response: Return of consciousness and spontaneous ventilation within 1-2 minutes
• Maximum dose: 1 mg for procedural sedation reversal
• Document time and dose administered

(d) Re-sedation Phenomenon (5 marks)

Pharmacokinetic Basis (3 marks):

• Flumazenil half-life: 40-80 minutes (mean approximately 54 minutes)
• Midazolam half-life: 1.5-2.5 hours (prolonged in this patient due to elderly age, diltiazem interaction, and metabolite accumulation)
• After flumazenil effect wears off (45-90 minutes), remaining midazolam re-occupies benzodiazepine receptors
• In this patient, midazolam levels remain elevated due to:
  • Reduced CYP3A4 metabolism (diltiazem)
  • Reduced clearance (elderly)
  • Potential metabolite accumulation (renal impairment)
• Result: Re-sedation occurs as flumazenil is eliminated faster than midazolam

Management (2 marks):

1. Repeat flumazenil 0.2-0.5 mg IV
2. Consider continuous flumazenil infusion: 0.1-0.4 mg/hr (two-thirds of effective bolus dose per hour)
3. Extended monitoring: minimum 4 hours given prolonged midazolam effect in this patient
4. Keep patient in monitored recovery area
5. Ensure IV access maintained throughout observation period
6. Document re-sedation episode and flumazenil doses
7. Clear discharge criteria: minimum 2 hours after last flumazenil dose with stable observations

Total: 20 marks

---

Viva Scenario (15 marks)

Stem: You are the anaesthetic registrar seeing a 35-year-old man in pre-admission clinic for elective laparoscopic cholecystectomy. He mentions that he is HIV-positive and is taking antiretroviral medications including ritonavir. He also expresses significant anxiety about the anaesthetic and asks about something to help him relax before surgery.

Expected Viva Progression:

Examiner: What information do you need about his HIV medications?

Candidate (2 marks):

• Specific antiretroviral regimen: ritonavir is a potent CYP3A4 inhibitor
• Duration of treatment and adherence
• Other medications (check for other CYP interactions)
• CD4 count and viral load (assess disease control)
• Any opportunistic infections or organ involvement

Examiner: He is on a regimen containing ritonavir 100 mg twice daily. Why is this relevant to midazolam?

Candidate (3 marks):

• Ritonavir is one of the most potent CYP3A4 inhibitors known
• Midazolam is predominantly metabolised by CYP3A4 to 1-hydroxymidazolam
• Co-administration can increase midazolam AUC by 5-30 fold (studies show up to 28-fold increase)
• Half-life prolonged from 1.5-2.5 hours to potentially greater than 24 hours
• Oral midazolam is particularly affected due to inhibition of intestinal and hepatic CYP3A4
• Even IV midazolam duration significantly prolonged

Examiner: How would you manage his request for anxiolysis?

Candidate (3 marks):

Option 1 - Avoid midazolam:

• Use lorazepam instead: metabolised by glucuronidation only, not affected by CYP3A4
• Dose: 1-2 mg PO/SL 1-2 hours preoperatively

Option 2 - Use midazolam with caution:

• If IV midazolam chosen, reduce dose by 75-90%
• Initial dose: 0.25-0.5 mg IV maximum
• Titrate very slowly
• Expect prolonged sedation

Alternative approaches:

• Non-pharmacological: explanation, reassurance, music, distraction
• Alternative medications: low-dose clonidine, dexmedetomidine

Examiner: You decide to use lorazepam for premedication. Explain why lorazepam is less affected by ritonavir.

Candidate (2 marks):

• Lorazepam undergoes direct glucuronidation (Phase II metabolism) by UGT enzymes
• It does NOT undergo CYP450-mediated Phase I oxidation
• Therefore, CYP3A4 inhibitors (ritonavir) do not affect lorazepam metabolism
• This makes lorazepam the benzodiazepine of choice in patients on CYP3A4 inhibitors
• Similarly suitable in hepatic impairment where CYP activity is reduced

Examiner: During surgery, you use propofol/remifentanil TIVA. The surgeon asks for muscle relaxation. The patient had 2 mg lorazepam premedication. How do you reverse the lorazepam at the end?

Candidate (3 marks):

• Lorazepam can be reversed with flumazenil if significant residual sedation
• However, lorazepam half-life (10-20 hours) is much longer than flumazenil (40-80 minutes)
• High re-sedation risk

Approach:

• Assess need for reversal: is the patient adequately awake?
• If not, consider whether sedation is from lorazepam or other causes
• If flumazenil indicated: 0.2 mg IV, titrate
• Extended monitoring essential: minimum 4-6 hours given lorazepam's long half-life
• Consider overnight admission if significant lorazepam effect

Examiner: What are the contraindications to flumazenil?

Candidate (2 marks):

1. Chronic benzodiazepine dependence (withdrawal seizure risk)
2. Mixed overdose with tricyclic antidepressants (unmasks TCA seizure risk)
3. Patients receiving benzodiazepines for seizure control (epilepsy)
4. Known seizure disorder managed with benzodiazepines
5. Raised intracranial pressure (withdrawal response may worsen ICP)

Total: 15 marks

---

References

1. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985;62(3):310-324. PMID: 3156545

2. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam: a review of its pharmacological properties and therapeutic use. Drugs. 1984;28(6):519-543. PMID: 6394264

3. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27-35. PMID: 6742481

4. Kanto JH. Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. Pharmacotherapy. 1985;5(3):138-155. PMID: 3161005

5. Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;346(8968):145-147. PMID: 7603229

6. Swart EL, Zuideveld KP, de Jongh J, et al. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol. 2004;57(2):135-145. PMID: 14748812

7. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263-306. PMID: 23269131

8. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. PMID: 30113379

9. Fryer RI, Zhang P, Rios R, et al. Structure-activity relationships of pyrrolo[2,1-c][1,4]benzodiazepine antitumor agents. J Med Chem. 1992;35(25):4790-4796. PMID: 1469704

10. Walser A, Benjamin LE, Flynn T, Mason C, Schwartz R, Fryer RI. Quinazolines and 1,4-benzodiazepines. 84. Synthesis and reactions of imidazo[1,5-a][1,4]benzodiazepines. J Org Chem. 1978;43(5):936-944. PMID: 24878

11. Gerecke M. Chemical structure and properties of midazolam compared with other benzodiazepines. Br J Clin Pharmacol. 1983;16 Suppl 1:11S-16S. PMID: 6138067

12. Crevat-Pisano P, Dragna S, Granthil C, Coassolo P, Cano JP, Francois G. Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. J Pharm Pharmacol. 1986;38(8):578-582. PMID: 2876086

13. Pieri L, Schaffner R, Scherschlicht R, et al. Pharmacology of midazolam. Arzneimittelforschung. 1981;31(12a):2180-2201. PMID: 6120698

14. Elliott HW. Metabolism of lorazepam. Br J Anaesth. 1976;48(11):1017-1023. PMID: 10933

15. Heizmann P, Ziegler WH. Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung. 1981;31(12a):2220-2223. PMID: 6120700

16. Sigel E, Buhr A. The benzodiazepine binding site of GABAA receptors. Trends Pharmacol Sci. 1997;18(11):425-429. PMID: 9426470

17. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300(1):2-8. PMID: 11752090

18. Sieghart W. Structure, pharmacology, and function of GABAA receptor subtypes. Adv Pharmacol. 2006;54:231-263. PMID: 17175817

19. Study RE, Barker JL. Diazepam and (--)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons. Proc Natl Acad Sci USA. 1981;78(11):7180-7184. PMID: 6273918

20. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989;25(3):213-220. PMID: 2471436

21. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401(6755):796-800. PMID: 10548105

22. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3(6):587-592. PMID: 10816315

23. Collinson N, Kuenzi FM, Jarolimek W, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci. 2002;22(13):5572-5580. PMID: 12097508

24. Cheng VY, Martin LJ, Elliott EM, et al. Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J Neurosci. 2006;26(14):3713-3720. PMID: 16597725

25. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009;56(1):141-148. PMID: 18760291

26. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994;47(9):1643-1653. PMID: 8185679

27. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 1989;36(1):89-96. PMID: 2787473

28. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth. 1994;73(5):658-661. PMID: 7826798

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols in clinical practice.